1. Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell Lymphoma.
- Author
-
Xu, Qinghua, Tan, Cong, Ni, Shujuan, Wang, Qifeng, Sheng, Weiqi, Du, Xiang, Wu, Fei, Ye, Xun, Meng, Xia, and Liu, Fang
- Subjects
- *
GENE expression , *B cell lymphoma , *LYMPHOMAS , *CARCINOGENESIS , *BIOMARKERS , *DISEASES , *PROGNOSIS - Abstract
The division of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes based on gene expression profiling has proved to be a landmark in understanding the pathogenesis of the disease. This study aims to identify a novel biomarker to facilitate the translation of research into clinical practice. Using a training set of 350 patients, we identified a two-gene expression signature, 'LIMD1-MYBL1 Index', which is significantly associated with cell-of-origin subtypes and clinical outcome. This two-gene index was further validated in two additional dataset. Tested against the gold standard method, the LIMD1-MYBL1 Index achieved 81% sensitivity, 89% specificity for ABC group and 81% sensitivity, 87% specificity for GCB group. The ABC group had significantly worse overall survival than the GCB group (hazard ratio = 3.5, P = 0.01). Furthermore, the performance of LIMD1-MYBL1 Index was satisfactory compared with common immunohistochemical algorithms. Thus, the LIMD1-MYBL1 Index had considerable clinical value for DLBCL subtype classification and prognosis. Our results might prompt the further development of this two-gene index to a simple assay amenable to routine clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF